Yibo Dai, Anne Knisely, Mitsutake Yano, Minghao Dang, Emily M. Hinchcliff, Sanghoon Lee, Annalyn Welp, Manoj Chelvanambi, Matthew Lastrapes, Heng Liu, Zhe Yuan, Chen Wang, Hao Nie, Stephanie Jean, Luis J. Montaner, Jiakai Hou, Ami Patel, Shrina Patel, Bryan Fellman, Ying Yuan, Baohua Sun, Renganayaki Krishna Pandurengan, Edwin Roger Parra Cuentas, Joseph Celestino, Yan Liu, Jinsong Liu, R. Tyler Hillman, Shannon N. Westin, Anil K. Sood, Pamela T. Soliman, Aaron Shafer, Larissa A. Meyer, David M. Gershenson, David Vining, Dhakshinamoorthy Ganeshan, Karen Lu, Jennifer A. Wargo, Weiyi Peng, Rugang Zhang, Linghua Wang & Amir A. Jazaeri PPP2R1A mutations portend improved survival after cancer immunotherapy , Nature: 2025
Nacarelli T, Fukumoto T, Zundell JA, Fatkhutdinov N, Jean S, Cadungog MG, Borowsky ME, Zhang R NAMPT Inhibition Suppresses Cancer Stem-like Cells Associated with Therapy-Induced Senescence in Ovarian Cancer. , Cancer Res, 80(4):890-900: 2020
Karakashev S, Fukumoto T, Zhao B, Lin J, Wu S, Fatkhutdinov N, Park PH, Semenova G, Jean S, Cadungog MG, Borowsky ME, Kossenkov AV, Liu Q, Zhang R EZH2 Inhibition Sensitizes CARM1-High, Homologous Recombination Proficient Ovarian Cancers to PARP Inhibition. , Cancer Cell, 37(2):157-167.e6: 2020
Zhao B, Lin J, Rong L, Wu S, Deng Z, Fatkhutdinov N, Zundell J, Fukumoto T, Liu Q, Kossenkov A, Jean S, Cadungog MG, Borowsky ME, Drapkin R, Lieberman PM, Abate-Shen CT, Zhang R ARID1A promotes genomic stability through protecting telomere cohesion. , Nat Commun, 10(1):4067: 2019
Fukumoto T, Zhu H, Nacarelli T, Karakashev S, Fatkhutdinov N, Wu S, Liu P, Kossenkov AV, Showe LC, Jean S, Zhang L, Zhang R N6-methylation of adenosine (m6A) of FZD10 mRNA contributes to PARP inhibitor resistance. , Cancer Res, 79(11):2812-2820: 2019
Singha B, Harper SL, Goldman AR, Bitler BG, Aird KM, Borowsky ME, Cadungog MG, Liu Q, Zhang R, Jean S, Drapkin R, Speicher DW CLIC1 and CLIC4 complement CA125 as a diagnostic biomarker panel for all subtypes of epithelial ovarian cancer. , Sci Rep, 8(1):14725: 2018
Fukumoto T, Park P, Wu S, Fatkhutdinov N, Karakashev S, Nacarelli T, Kossenkov AV, Speicher DW, Jean S, Zhang L, Wang T, Shih I, Conejo-Garcia JR, Bitler BG, Zhang R Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer. , Cell Rep, 22(13):3393-3400: 2018
George E, Kim H, Krepler C, Wenz B, Makvandi M, Tanyi JL, Brown E, Zhang R, Brafford P, Jean S, Mach RH, Lu Y, Mills GB, Herlyn M, Morgan M, Zhang X, Soslow R, Drapkin R, Johnson N, Zheng Y, Cotsarelis G, Nathanson KL, Simpkins F A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers. , JCI Insight, 2(1):e89760: 2017
Jean S, Li J, Katsaros D, Wubbenhorst B, Maxwell KN, Fishbein L, Mclane MW, Benedetto C, Canuto EM, Mitra N, Zhang L, Nathanson KL, Tanyi, JL Paclitaxel is necessary for improved survival in epithelial ovarian cancers with homologous recombination gene mutations. , Oncotarget, 7(30):48577-48585: 2016
Jean S, Li J, Wubbenhorst B, Maxwell KN, Fishbein L, Mclane MW, Mitra N, Zhang L, Nathanson KL, Tanyi, JL Paclitaxel is necessary for improved survival in epithelial ovarian cancers with somatic homologous recombination gene mutations. Abstract presented, , American Association for Cancer Research Annual Meeting, Washington, DC: 2015
